Literature DB >> 28969152

Azathioprine in Chronic Recalcitrant Erythema Nodosum Leprosum: A Case Report.

Singh Shailendra Vikram Jitendra1, Romita Bachaspatimayum2, A Subhalakshmi Devi3, S Rita3.   

Abstract

Erythema Nodosum Leprosum (ENL) may have a chronic course which may be recalcitrant to treatment. Preferred treatment modalities are systemic corticosteroids and thalidomide. Azathioprine, methotrexate and cyclosporine are immunosuppressants which may also be used as a steroid sparing agent. We report the case of a 48-year-old male diagnosed as lepromatous leprosy that developed ENL after four months of Multibacillary Multi-Drug Therapy (MB-MDT). He was treated with oral prednisolone (1 mg/kg/day) which was gradually tapered upto a dose of 7.5 mg/day. He developed recurrences on and off once the dose reached the said level and this continued for three years. Oral clofazamine (300 mg/day x 6 months; then 100 mg/day x 6 months) was also added in the second year. Thalidomide (200 mg/day) was also given but withdrawn due to adverse effect after 10 days. Azathioprine was started at a dose of 100 mg/day following which there was resolution of symptoms by one week and no recurrences by 10 weeks; it was given for eight months after which the dose was tapered to 50 mg/day for another four months. Complete withdrawal of oral prednisolone after gradual tapering was possible by 12 months of azathioprine therapy. The patient is still on regular follow-up with no recurrences so far till the last check-up.

Entities:  

Keywords:  Corticosteroid; Lepra reaction; Lepromatous leprosy

Year:  2017        PMID: 28969152      PMCID: PMC5620793          DOI: 10.7860/JCDR/2017/26536.10499

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  7 in total

1.  Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum.

Authors:  Vikram K Mahajan; N L Sharma; R C Sharma; Ashok Sharma
Journal:  Lepr Rev       Date:  2003-06       Impact factor: 0.537

2.  British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011.

Authors:  S J Meggitt; A V Anstey; M F Mohd Mustapa; N J Reynolds; S Wakelin
Journal:  Br J Dermatol       Date:  2011-10       Impact factor: 9.302

3.  Role of azathioprine in preventing recurrences in a patient of recurrent erythema nodosum leprosum.

Authors:  Kaushal K Verma; P Srivastava; Anil Minz; Kamna Verma
Journal:  Lepr Rev       Date:  2006-09       Impact factor: 0.537

4.  Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.

Authors:  Leonor Pocaterra; Suman Jain; Rajgopal Reddy; Syed Muzaffarullah; Obdulita Torres; Sujai Suneetha; Diana N J Lockwood
Journal:  Am J Trop Med Hyg       Date:  2006-05       Impact factor: 2.345

Review 5.  Interventions for erythema nodosum leprosum. A Cochrane review.

Authors:  Natasja H J Van Veen; Diana N J Lockwood; Wim H Van Brakel; J Ramirez; Jan Hendrik Richardus
Journal:  Lepr Rev       Date:  2009-12       Impact factor: 0.537

Review 6.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 7.  The role of thalidomide in the management of erythema nodosum leprosum.

Authors:  Steven L Walker; Michael F R Waters; Diana N J Lockwood
Journal:  Lepr Rev       Date:  2007-09       Impact factor: 0.537

  7 in total
  3 in total

1.  Chronic recalcitrant erythema nodosum leprosum: therapeutic dilemma and role of mycobacterium indicus pranii vaccine.

Authors:  Sunil Kumar Gupta; Sushantika Kumari
Journal:  An Bras Dermatol       Date:  2021-11-27       Impact factor: 1.896

2.  Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports.

Authors:  Pugazhenthan Thangaraju; Sajitha Venkatesan; Meenalotchini Gurunthalingam; Shoban Babu; Tamilselvan T
Journal:  Rev Soc Bras Med Trop       Date:  2020-09-11       Impact factor: 1.581

3.  A Challenging Case of Domestically Acquired Leprosy in the Southern United States.

Authors:  Shruthi Mohan; Jessica K Fairley
Journal:  Open Forum Infect Dis       Date:  2020-02-21       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.